Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Yalcin, S.
Right arrow Articles by Kars, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yalcin, S.
Right arrow Articles by Kars, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 33:580-583 (2003)
© 2003 Foundation for Promotion of Cancer Research

Biweekly Irinotecan Plus Bolus 5-Fluorouracil and Folinic Acid in Patients with Advanced Stage Colorectal Cancer

Suayib Yalcin, Berna Oksuzoglu, Gülten Tekuzman, Hüseyin Engin, Ismail Celik, Alev Turker, Ibrahim Barista, Ibrahim Gullu, Nilufer Guler, Kadri Altundag, Yavuz Ozisik and Ayse Kars+

Department of Medical Oncology, Institute of Oncology, Hacettepe University, Ankara, Turkey

Objective: In this study, we evaluated the efficacy and tolerability of biweekly irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and folinic acid (FA) regimen (IFL) in patients with advanced stage colorectal cancer.

Methods: A total of 28 patients were examined. The median age was 51 years (range, 30–74 years). One treatment cycle consisted of CPT-11 180 mg/m2 on days 1 and 15; 5-FU 425 mg/m2 on days 1, 2, 15 and 16; and FA 20 mg/m2 on days 1, 2, 15 and 16, every 4 weeks. A total of 119 cycles (median, 4.0 cycles) were administered. Of the 28 patients, 18 received the chemotherapy as first line treatment, seven received it as second line and three received it as third line.

Results: An overall objective response rate of 21.5% was achieved in the patient group. However, the overall response rate for the 18 patients receiving first line treatment was 27.7%. The median response duration was 10.5 months (range, 3–19 months). An additional 28.6% of the patients had stable disease for a median duration of 6.5 months (range, 3–8 months). Median time to disease progression was 4.5 months (range, 1–22+ months) and median overall survival time was 11+ months (95% confidence interval, 9–15 months). Toxicities were mild and manageable.

Conclusions: We conclude that biweekly IFL is a practical and tolerable treatment option with a disease control rate of 50.1% in patients with advanced stage colorectal cancer.

+ For all reprints and correspondence: Suayib Yalcin, Department of Medical Oncology, Institute of Oncology, Hacettepe University, Sihhiye 06100, Ankara, Turkey. E-mail: syalcin{at}hacettepe.edu.tr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.